Ceryx has strengthened its Board of Directors with the appointment of Mark Strong, a highly respected medical devices executive with decades of global leadership experience.
Mark has held numerous senior executive roles in heart failure therapy development including Vice President of R&D at Abbott, Boston Scientific, and HeartWare and most recently as CEO of Heart Failure Solutions. He brings deep expertise in developing and commercializing breakthrough cardiovascular technologies.
Mark’s appointment comes at a pivotal moment for Ceryx as the company completes a successful first-in-human trial of its novel cardiac rhythm management device. The technology is designed to improve the efficiency of the failing heart and to activate the heart’s own repair mechanisms—a development the company believes could redefine treatment for heart failure patients.
Dr Stuart Plant, CEO of Ceryx Medical, said: “I am delighted to welcome Mark to the Board as a Non-Executive Director. He brings a wealth of experience and insight to Ceryx.
Attracting someone of Mark’s caliber is a strong endorsement of our technology and our mission. Mark shares our ambition to transform the lives of people living with heart failure, and his experience will be valuable as we move into the next stage development.”
“Very few devices have captured my attention the way this one has. Ceryx technology has the potential to meaningfully improve cardiac output and support cardiac recovery in heart
failure patients. Stuart and the team have done exceptional work, and I’m pleased to support this next phase of growth.”
Heart failure affects more than 20 million people across Europe and the US and remains the leading cause of hospitalization in people over 65. Once diagnosed, the disease is difficult to halt, with around half of patients dying within five years.
“This is an exceptionally exciting period for the company,” Dr Plant added. “We are confident that our technology can change the outlook for heart failure patients. We also believe our core platform has potential applications in other conditions, including hypertension and spinal cord injuries, giving us the foundations for a strong future pipeline of breakthrough therapies.”
Ceryx Medical has attracted interest from partners and investors in the UK and abroad, with backing from leading MedTech investors including BGF, ParkWalk, and the Development Bank of Wales.